DynamX (coronary implant)

History

2024: Product Announcement

At the end of October 2024, Elixir Medical introduced the DynamX coronary implant for the treatment of coronary heart disease, which is able to adapt to human vessels. Data from studies show that DynamX was more effective than a standard drug-eluting stent, especially in complex and diverse patient populations, including those with acute coronary syndrome (ACS) and small vessel lesions.

Despite many studies, the installation of drug-eluting stents is associated with an increase in the incidence of adverse events by 2-3% per year, which affects up to 40-50% of patients over 10 years. According to the developers, the DynamX implant must solve this problem through a unique design and mechanism of action, deployed in three phases.

𝓲

Elixir Medical

After implantation into the installation phase, the new stent maximally expands the lumen of the vessel to restore blood flow and stop the symptoms of coronary heart disease. The second phase begins after the body encapsulates the device, surrounding it with its own tissues. As a result, the absorbable polymer coating resorbs and allows the spiral filaments of the bioadapter to separate from each other. As a result, the implant adjusts to the shape of the vessel and its growth, still maintaining the installed lumen. The third phase provides adaptive dynamic support for the vessel by separated helical filaments. In this phase, the implant restores vessel viability and hemodynamic modulation by returning vessel wall compliance, adaptive blood flow volume, plaque stabilization and regression.

Based on the first data from the studies, the DynamX implant received the status of a breakthrough device in early 2024. In addition, the system has also received CE labeling, although research is still ongoing.^[1]

Notes